LG Chem Submits Phase 3 Clinical Trial Application for Gout Treatment in Italy

LG Chem is accelerating the development of its gout treatment, Tigulixostat. After the United States, the company has submitted a plan for phase 3 clinical trials in Europe.

According to the electronic disclosure system of the Financial Supervisory Service on Aug. 21, LG Chem has applied for the global phase 3 clinical trial of Tigulixostat with the Italian Medicines Agency (AIFA).

The objective of this phase 3 trial is to assess the efficacy and safety of Tigulixostat in reducing serum uric acid levels in hyperuricemic gout patients. The trial will involve 2,600 participants over 12 months.

LG Chem stated, “We have submitted clinical trial plans for the gout treatment to multiple countries outside of the U.S. and are conducting clinical trials. We also plan to proceed with trials in Europe.”